Drugs / Tipiracil
Tipiracil
also known as
tipiracil hydrochloride · TPI · TAS-1-462 · Tipiracil hydrochloride component of lonsurf · Tipiracil hydrochloride component of s-95005 · Tipiracil hydrochloride component of tas-102 · Tipiracilo · TPI (freebase)
Small molecule targets TYMP via inhibition
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed colorectal cancer 3 milestones | |||||
| Filed | US (FDA) | LONSURF | colorectal cancer | 2023-04-18 | “the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental new drug application (sNDA) for trifluridine/tipiracil (LONSURF®)” taihooncology.com ↗ |
| Filed | Other | — | colorectal cancer | 2017-10-20 | “Health Canada accepted for review Taiho’s New Drug Submission (NDS) for trifluridine (FTD) and tipiracil (TPI)” taihooncology.com ↗ |
| Filed | US (FDA) | — | colorectal cancer | 2014-12-22 | “the New Drug Application (NDA) for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), has been accepted for review by the U.S. Food and Drug Administration (FDA)” taihooncology.com ↗ |
| Filed gastroesophageal adenocarcinoma 1 milestone | |||||
| Filed | US (FDA) | LONSURF | gastroesophageal adenocarcinoma | 2018-10-25 | “the United States Food and Drug Administration (FDA) has accepted and granted priority review for the supplemental New Drug Application (sNDA) for LONSURF®...” taihooncology.com ↗ |
| Approved Indication not stated 2 milestones | |||||
| Approved | EU (EMA) | Lonsurf | — | 2016-04-25 | europa.eu ↗ |
| Approved | US (FDA) | LONSURF | — | 2015-09-22 | fda.gov ↗ |
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04511039 | Jun 2021 → Sep 2028 expected | colorectal adenocarcinoma, gastroesophageal junction adenocarcinoma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT04104139 | Dec 2019 → Sep 2024 overdue | rectum adenocarcinoma | OHSU Knight Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03616574 | Apr 2019 → Feb 2022 | colorectal cancer | Holy Stone Healthcare Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03317119 | Apr 2018 → Jul 2023 | colon carcinoma, rectal carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05927857 | Apr 2024 → Dec 2027 expected | gastric adenocarcinoma | National Health Research Institutes, Taiwan | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04177602 | Nov 2019 → Sep 2022 | — | University Medical Center Hamburg-Eppendorf | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03368963 | Jan 2018 → Jun 2025 overdue | cholangiocarcinoma, colorectal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma | Emory University | Active not recruiting | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT07535632 | Jun 2026 → Jun 2028 expected | colorectal neoplasm | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07146646 | Dec 2025 → Feb 2027 expected | cholangiocarcinoma, gallbladder carcinoma | Case Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07011550 | Aug 2025 → Jul 2028 | colorectal cancer | M.D. Anderson Cancer Center | Suspended | No outcome recorded |
| Phase 2 | NCT06711471 | Nov 2024 → Nov 2026 expected | gastric adenocarcinoma | LIN YANG | Recruiting | No outcome recorded |
| Phase 2 | NCT06485713 | Mar 2024 → Jun 2026 overdue | colorectal cancer | First Affiliated Hospital of Wenzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT05356897 | Oct 2023 → Sep 2024 | colon adenocarcinoma, rectum adenocarcinoma | Academic and Community Cancer Research United | Withdrawn | No outcome recorded |
| Phase 2 | NCT04660760 | Jun 2021 → Jul 2024 | gastric adenocarcinoma, gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Academic and Community Cancer Research United | Unknown | No outcome recorded |
| Phase 2 | NCT04076761 | Dec 2019 → Sep 2022 | cholangiocarcinoma | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03981614 | Oct 2019 → Aug 2021 | colorectal carcinoma | Academic and Community Cancer Research United | Completed | No outcome recorded |
| Phase 2 | NCT04042714 | Aug 2019 → Sep 2025 | neuroendocrine neoplasm | Baylor Research Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04294264 | Feb 2019 → Mar 2024 overdue | colon carcinoma | Rutgers, The State University of New Jersey | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03844620 | Jan 2019 → Aug 2026 overdue | colorectal carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03274882 | Mar → Dec 2017 | colorectal cancer | Servier | Completed | No outcome recorded |
| Phase 2 | NCT01904253 | Jul 2013 → Jun 2014 | small cell lung carcinoma | Taiho Oncology, Inc. | Terminated | No outcome recorded |
| Phase 35 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT07525206 | May 2026 → May 2029 expected | colorectal cancer | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT07483684 | Mar 2026 → Aug 2027 expected | carcinoma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04457297 | Jul 2020 → Jul 2024 | colorectal cancer | National Cancer Center Hospital East | Completed | Missed primary |
| Phase 3 | NCT03306394 | Oct 2016 → Nov 2020 | colorectal cancer | Servier | Completed | No outcome recorded |
| Phase 3 | NCT01607957 | Jun 2012 → Jan 2014 | colorectal cancer | Taiho Oncology, Inc. | Completed | Met primary |
| Phase not applicable2 trials | ||||||
| — | NCT07371871 | Jan 2026 → Dec 2027 expected | gastric cancer | Anhui Provincial Cancer Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06495463 | Mar 2022 → Dec 2024 | colorectal cancer | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Comparator or background therapy19 trials | ||||||
| Phase 0 | NCT07318389 Background | Jun 2026 → Nov 2027 expected | colorectal cancer | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05130060 Background | Jan 2022 → Jun 2023 | colon adenocarcinoma, metastatic malignant neoplasm in the colon, rectum adenocarcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT03715933 Background | Oct 2018 → Dec 2028 expected | Ewing sarcoma, colorectal adenocarcinoma | Inhibrx Biosciences, Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05405595 Background | Jun 2022 → Oct 2026 expected | — | Adagene Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05438459 Comparator | Jun 2022 → Mar 2032 expected | gastric cancer, malignant pancreatic neoplasm | Kyushu University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05083481 Background | Oct 2021 → May 2026 | — | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT04393298 Background | Jul 2020 → Apr 2024 | cancer | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 2 | NCT06039202 Background | Dec 2027 → Oct 2030 | colorectal cancer | Holy Stone Healthcare Co., Ltd | Suspended | No outcome recorded Stop: Business |
| Phase 2 | NCT07353268 Comparator | Jan 2026 → Aug 2027 expected | colorectal cancer | Tao Zhang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07387081 Background | Dec 2025 → May 2028 expected | — | LaNova Medicines Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT06856837 Comparator | Oct 2025 → Dec 2029 expected | colorectal cancer | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting | No outcome recorded |
| Phase 2 | NCT06680622 Background | Mar 2025 → Sep 2027 expected | gastroesophageal adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05608044 Comparator | Nov 2022 → Sep 2027 expected | colorectal cancer | Agenus Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04854434 Comparator | Jun 2021 → Jun 2022 | colorectal cancer | Karyopharm Therapeutics Inc | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03992456 Comparator | Apr 2020 → Dec 2023 | colon adenocarcinoma, rectum adenocarcinoma | Academic and Community Cancer Research United | Unknown | Missed primary |
| Phase 3 | NCT06992648 Comparator | Apr 2025 → Dec 2027 expected | colorectal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 3 | NCT05198934 Comparator | Apr 2022 → Jul 2025 | colorectal cancer | Amgen | Completed | Met primary |
| Phase 3 | NCT04879368 Comparator | May 2021 → Jan 2025 | gastroesophageal cancer | Australasian Gastro-Intestinal Trials Group | Completed | Missed primary |
| Phase 3 | NCT03717038 Comparator | Feb 2019 → Dec 2023 | colorectal carcinoma | Symphogen A/S | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 24
| Date | Issuer | Release |
|---|---|---|
| 2025-10-13 | AbbVie | Results AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors abbvie.com ↗
Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 67% and 65% of patients, respectively. |
| 2025-01-22 | Agenus Inc. | Results Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease agenusbio.com ↗
Standard of care had no responses. |
| 2023-08-02 | Taiho Oncology, Inc. | Regulatory FDA Approves LONSURF® (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC) taihooncology.com ↗ |
| 2023-05-03 | Taiho Oncology, Inc. | Results Taiho Oncology and Servier Announce Publication in the New England Journal of Medicine of Pivotal Phase 3 Data for Trifluridine/Tipiracil (LONSURF®) in Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer taihooncology.com ↗
In addition, the median time to worsening of ECOG (Eastern Cooperative Oncology Group) performance-status score was significantly delayed in patients receiving the investigational combination of trifluridine/tipiracil and bevacizumab. |
| 2023-04-18 | Taiho Oncology, Inc. | Regulatory U.S. Food and Drug Administration Accepts for Priority Review Taiho Oncology’s Supplemental New Drug Application for the Use of Trifluridine/Tipiracil (LONSURF®) in Combination With Bevacizumab for Refractory Metastatic Colorectal Cancer taihooncology.com ↗ |
| 2023-01-17 | Taiho Oncology, Inc. | Results Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium taihooncology.com ↗
This improvement in OS represents a 39% reduction in the risk of death in patients with refractory mCRC. |
| 2022-09-12 | Taiho Oncology, Inc. | Results Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer taihooncology.com ↗
Combining trifluridine/tipiracil with bevacizumab demonstrated the potential to extend survival in these patients who have limited therapeutic options. |
| 2020-01-25 | Taiho Oncology, Inc. | Results Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Futibatinib (TAS-120) at ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) taihooncology.com ↗
hematologic adverse events with LONSURF in subgroups of patients with mild to moderate renal impairment and mild hepatic impairment were manageable and similar to those in the overall patient population. |
| 2019-10-14 | Taiho Oncology, Inc. | Results Analysis of Patients with Prior Gastrectomy Treated with LONSURF® (trifluridine and tipiracil) Published in JAMA Oncology taihooncology.com ↗
The safety profile of LONSURF was consistent with studies of the drug in metastatic colorectal cancer (mCRC), and no new safety concerns were reported. |
| 2019-02-25 | Taiho Oncology, Inc. | Regulatory FDA Approves Taiho Oncology’s LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma taihooncology.com ↗ |
| 2019-01-17 | Taiho Oncology, Inc. | Results Taiho Oncology and Servier Present Data on LONSURF® (trifluridine/tipiracil) at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI) taihooncology.com ↗
The results confirmed that LONSURF prolonged survival versus placebo regardless of prior gastrectomy. |
| 2018-10-25 | Taiho Oncology, Inc. | Regulatory FDA Accepts Supplemental New Drug Application for LONSURF® (trifluridine/tipiracil) for the Treatment of Metastatic Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma; Grants Priority Review taihooncology.com ↗ |
| 2018-10-21 | Taiho Oncology, Inc. | Results Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology taihooncology.com ↗
The trial met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS), as well as continued to demonstrate LONSURF’s predictable safety and tolerability profile. |
| 2018-09-28 | Taiho Oncology, Inc. | Results Taiho Oncology Presents Real-World Adherence Data for LONSURF® (trifluridine and tipiracil) in Metastatic Colorectal Cancer at ASCO Quality of Care Symposium taihooncology.com ↗
Treatment with LONSURF was associated with significantly higher medication adherence and longer time to discontinuation compared to treatment with regorafenib. |
| 2018-06-21 | Taiho Oncology, Inc. | Results Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) at ESMO 20th World Congress on Gastrointestinal Cancer 2018 taihooncology.com ↗
This trial met its primary endpoint of overall survival (OS) and secondary endpoint measures of progression-free survival (PFS), and safety and tolerability, as well as quality of life. |
| 2018-06-14 | Taiho Oncology, Inc. | Results Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compound TAS-120 at ESMO 20th World Congress on Gastrointestinal Cancer 2018 taihooncology.com ↗
A pivotal Phase III trial (TAGS) evaluating LONSURF® plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated metastatic gastric cancer refractory to standard therapies met its primary endpoint of prolonged overall survival (OS) (Abstract LBA-002). |
| 2018-05-09 | Taiho Oncology, Inc. | Results Taiho Oncology Announces Positive Topline Results from Pivotal Phase 3 Trial of LONSURF® (trifluridine/tipiracil) in Metastatic Gastric Cancer taihooncology.com ↗ |
| 2018-01-20 | Taiho Oncology, Inc. | Results Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Metastatic Colorectal Cancer (mCRC) Data at ASCO 2018 Gastrointestinal Cancers Symposium taihooncology.com ↗
Taiho Oncology, Inc. and Servier today announced clinical data for LONSURF® (trifluridine and tipiracil) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild type, an anti-EGFR therapy. |
| 2017-10-20 | Taiho Oncology, Inc. | Regulatory Health Canada Grants Priority Review Status to trifluridine and tipiracil for Refractory Metastatic Colorectal Cancer taihooncology.com ↗ |
| 2015-09-22 | Taiho Oncology, Inc. | Regulatory Taiho Oncology, Inc. Announces FDA Approval of LONSURF® (trifluridine and tipiracil) for Refractory Metastatic Colorectal Cancer (mCRC) taihooncology.com ↗
today announced that the U.S. Food and Drug Administration (FDA) approved LONSURF® (trifluridine and tipiracil), formerly known as TAS-102 |
| 2015-02-23 | Taiho Oncology, Inc. | Regulatory Taiho Oncology, Inc. Announces TAS-102 New Drug Application for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA taihooncology.com ↗
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced the New Drug Application (NDA) for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), has been accepted for review by the U.S. Food and Drug Administration (FDA). |
| 2014-12-22 | Taiho Oncology, Inc. | Regulatory Taiho Oncology Completes Submission of TAS-102 New Drug Application to the US Food and Drug Administration for the Treatment of Refractory Metastatic Colorectal Cancer taihooncology.com ↗
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced that it has completed its rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride). |
| 2014-10-20 | Taiho Oncology, Inc. | Regulatory Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer taihooncology.com ↗
“We are pleased that TAS-102 has been granted Fast Track designation" said Fabio Benedetti, Senior Vice President and Chief Medical Officer at Taiho Oncology. |
| 2014-06-28 | Taiho Oncology, Inc. | Results Taiho Oncology, Inc. Announces Results from TAS-102 Global Phase III RECOURSE Trial in Refractory Metastatic Colorectal Cancer taihooncology.com ↗
TAS-102 achieved statistically significant improvements in overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC) whose disease had progressed after or who were intolerant to standard therapies. |
All press releases naming this drug 33 releases
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 50 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tipiracil | “TAS-102 is a novel combination medicinal product consisting of a thymidine-based nucleoside analogue (trifluridine; FTD) as the active component and the thymidine phosphorylase...” NCT04042714 ↗37“OBJECTIVES: TAS-102 is an oral combination treatment comprised of an antimetabolite, trifluridine, a thymidine-based nucleoside analog, and tipiracil hydrochloride, at a molar...” PMID 27597276 ↗ Jun 2016 “LONSURF is a cytotoxic combination treatment of 2 new drugs: trifluridine, a thymidine-based nucleoside analog, and tipiracil, an inhibitor of thymidine phosphorylase.” NCT03616574 ↗ “TAS-102 is a cytotoxic combination treatment of 2 drugs: trifluridine, a thymidine-based nucleoside analogue, and tipiracil an inhibitor of thymidine phosphorylase.” NCT06039202 ↗ “TAS-102 is a combination of trifluridine, a thymidine-based nucleic acid analogue, and tipiracil, a thymidine phosphorylase inhibitor.” NCT03717038 ↗ “TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil.” PMID 27443414 ↗ Jul 2016 “The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil.” NCT04879368 ↗ “Regorafenib. Fruquintinib. Trifluridine/Tipiracil (TAS-102) with or without Bevacizumab.” NCT07353268 ↗ “Drug:Trifluridine and Tipiracil Hydrochloride Tablets BID,Oral Administration” NCT07387081 ↗ “Regorafenib or trifluridine and tipiracil.” NCT05608044 ↗ |
| Known as | TAS-1-462 | ChEMBL registry synonym — accepted as the source's own label CHEMBL235668 ↗ |
| Known as | tipiracil hydrochloride | “Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride (with a molar ratio...” NCT03274882 ↗11“TAS-102 is a novel combination medicinal product consisting of a thymidine-based nucleoside analogue (trifluridine; FTD) as the active component and the thymidine phosphorylase...” NCT04042714 ↗ “FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride.” NCT04076761 ↗ “TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer.” PMID 25970050 ↗ May 2015 |
| Known as | Tipiracil hydrochloride component of lonsurf | ChEMBL registry synonym — accepted as the source's own label CHEMBL235668 ↗ |
| Known as | Tipiracil hydrochloride component of s-95005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL235668 ↗ |
| Known as | Tipiracil hydrochloride component of tas-102 | ChEMBL registry synonym — accepted as the source's own label CHEMBL235668 ↗ |
| Known as | Tipiracilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL235668 ↗ |
| Known as | TPI | “TAS-102 is a novel combination medicinal product consisting of a thymidine-based nucleoside analogue (trifluridine; FTD) as the active component and the thymidine phosphorylase...” NCT04042714 ↗1“The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in...” PMID 31912801 ↗ Jan 2020 |
| Known as | TPI (freebase) | ChEMBL registry synonym — accepted as the source's own label CHEMBL235668 ↗ |
| Action | Inhibit | “the thymidine phosphorylase inhibitor tipiracil” PMID 27443414 ↗ Jul 20161“Thymidine phosphorylase inhibitor” CHEMBL235668 ↗ |
| Modality | Small molecule | “Tipiracil is in a class of medications called thymidine phosphorylase inhibitors.” NCT05356897 ↗ |
| Route | Oral | “TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride” PMID 25970050 ↗ May 2015 |
| Target | TYMP | “Thymidine phosphorylase inhibitor” CHEMBL235668 ↗ |